Presentation at Drug Discovery Modality Study Group of JBA

We will be giving a pitch presentation at JBA (Japan Bioindustry Association) Drug Discovery Modality Study Group.

The theme of the 7th General Assembly is "Development of Drug Discovery through Innovation and Combination of Technologies".

Event Overview

Date and Time: Friday, July 18, 2025, 14:30–17:00*

*Our pitch presentation: 16:00-16:40

Venue: Hybrid of Online (Zoom) and Onsite (JBA Office)

Organizer: Japan Bioindustry Association (JBA), Drug Discovery Modality Study Group "Biomaterials Protective Hydrogels Support Drug Discovery Modality" We have developed zwitterionic hydrogel technology for long-term stabilization of biomaterials such as enzymes, nucleic acids, and proteins. This presentation will introduce the hydrogel technology that dramatically improves the storage stability, blood retention, and reaction efficiency of biopharmaceuticals with the successful examples.

Exhibit at BIO2025/Japan Pavilion

Gel Coat Biomaterials exhibited at the BIO International Convention 2025 (BIO2025),one of the largest global biotechnology exhibitions in Boston this year from June 16 to 19.

BIO2025 attracted many visitors, and they visited our booth at Japan Pavilion as well with great interest.

Many global companies and research institutions expressed interest in our hydrogel technologies, and we were able to discuss future collaborations.

54th Biomedical Polymers Symposium 2024 July 22-23, Tokyo, Japan.

We will present our latest research at the Research Group on Biomedical Polymers, to be held on July 22–23.

New charged zwitterionic polymer nanogels and functionalization of　biomolecules

Presenters: Satoshi Yamashita*, Shin Yoshida, and Madoka Takai

Zwitterionic polymers, with their inherent biocompatibility, offer a versatile platform for applications ranging from stabilization of biomaterials and implantable bioelectronic devices to novel medical treatments. They form hydrogels that can stabilize enzyme activity and hold promise for use in biofuel cells. This presentation will highlight zwitterionic polymer nanogels that provide new functionalities in biomolecules. We will discuss examples of successful stabilization of enzymes and proteins by our newly developed polymer hydrogels and the development of our latest advancements in creating novel materials for further biomolecular functionalization.

Zwitterionic polymer hydrogels and stabilization of enzymes (aiming for pharmaceuticals production)

Presenters: Maki Itoh*, Yuya Fukui, Satoshi Yamashita, Youichi Matsuo, Shin Yoshida, and Madoka Takai

Hydrogels based on polymers containing biocompatible zwitterionic groups are expected to be used for applications including stabilization of biomaterials, implantable bioelectronic devices, and novel medical treatments. They polymers form hydrogels that can stabilize enzyme activity and are promising materials for use in biofuel cells. The presentation focuses on polymerization reactions and nano-hydrogel formation, also touching on stabilization of enzymes. The presentation additionally refers to coating of hemocompatible copolymers. The coating reduced protein adsorption or blood coagulation with higher stability under fluidic conditions.

Zwitterionic Nanogels–Enzyme Hybrids: Development and Functional Evaluation

Presenters:Yuya Fukui*, Maki Itoh, Shin Yoshida, and Madoka Takai 

We are developing biocompatible hydrogel-based technologies designed to protect biomolecules (e.g., enzymes and proteins), leading to improved long-term stability and anti-fouling properties. In this study, we researched the use of zwitterionic polymer-based nanogels for enzyme immobilization to improve enzyme stability.

Using alkaline phosphatase (ALP) enzyme, we found that nanogel-immobilized ALP maintained high enzymatic activity and improved thermal stability (37℃) and protease resistance compared to non-treated ALP. The cellular uptake of the nanogels was dependent on their monomer composition, and cell-permeable nanogels were rapidly released from the cells. Cytotoxicity assays (up to 5 mg/mL) showed that the nanogel-immobilized ALP caused no significant toxicity, and no IC₅₀ value was observed. These results suggest that the developed nanogel system has extremely low toxicity in vivo. This nanogel system holds transformative potential for enzyme replacement therapy. Improved enzyme stability will enable lower doses and fewer administrations, reducing the burden on patients.

• Conferences & Exhibitions